Camurus AB (SE:CAMX)
:CAMX
CAMX Stock Chart & Stats
kr665.00
-kr17.00(-2.71%)
At close: 4:00 PM EST
kr665.00
-kr17.00(-2.71%)
Day’s Range― - ―
52-Week Rangekr430.80 - kr754.50
Previous CloseN/A
Volume19.01K
Average Volume (3M)126.83K
Market Cap
kr28.98B
Enterprise Valuekr25.27B
Total Cash (Recent Filing)kr3.73B
Total Debt (Recent Filing)kr106.03M
Price to Earnings (P/E)49.6
Beta0.76
Next Earnings
May 12, 2026EPS Estimate
3.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.67
Shares Outstanding59,934,734
10 Day Avg. Volume148,560
30 Day Avg. Volume126,834
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)8.62
Price to Sales (P/S)16.11
P/FCF Ratio49.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr685.00Price Target Upside3.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)14.64
Revenue Forecast (FY)kr2.79B
Bulls Say, Bears Say
Bulls Say
High Margins And Sustained ProfitabilityExceptionally high and stable gross margins (89–93%) combined with a 2025 net margin near 32% indicate durable earnings power. These margins provide structural resilience to cost or mix swings, supporting sustained operating cash generation and scalable profitability over the next 2–6 months.
Strong Cash Generation And Low LeverageRobust operating and free cash flow with high cash conversion improves financial flexibility and funds growth investments. Coupled with a very low debt profile, the balance sheet supports mid‑term launch spending and R&D without materially increasing leverage or refinancing risk.
Regulatory And Pipeline CatalystsRegulatory approvals and an upcoming FDA PDUFA create structurally meaningful upside: successful US approval and EU launches expand addressable markets and add new product revenue streams. Positive CAM2056 and ongoing CAM2029 programs further de-risk future franchise growth.
Bears Say
Inconsistent Top-line GrowthVolatile revenue trends reduce visibility for projecting earnings and cash flow. Even with strong margins, inconsistent sales hinder planning for commercial investment and make near‑term performance and milestone timing harder to predict over the next several quarters.
Market Access And Reimbursement BarriersStructural reimbursement, funding and physician‑remuneration barriers in major European markets limit adoption potential despite product efficacy. These systemic access constraints can persist for months and materially cap organic growth unless policy or funding models change.
Planned Material OpEx Increase For 2026Significant planned spending to support US launches and R&D will pressure margins in the medium term and requires successful execution. If launches or milestone receipts are delayed, higher OpEx raises funding needs and could compress free cash flow and operating profitability.
Camurus AB News
CAMX FAQ
What was Camurus AB’s price range in the past 12 months?
Camurus AB lowest stock price was kr430.80 and its highest was kr754.50 in the past 12 months.
What is Camurus AB’s market cap?
Camurus AB’s market cap is kr28.98B.
When is Camurus AB’s upcoming earnings report date?
Camurus AB’s upcoming earnings report date is May 12, 2026 which is in 35 days.
How were Camurus AB’s earnings last quarter?
Camurus AB released its earnings results on Feb 12, 2026. The company reported kr1.67 earnings per share for the quarter, missing the consensus estimate of kr2.367 by -kr0.697.
Is Camurus AB overvalued?
According to Wall Street analysts Camurus AB’s price is currently Undervalued.
Does Camurus AB pay dividends?
Camurus AB does not currently pay dividends.
What is Camurus AB’s EPS estimate?
Camurus AB’s EPS estimate is 3.45.
How many shares outstanding does Camurus AB have?
Camurus AB has 59,934,734 shares outstanding.
What happened to Camurus AB’s price movement after its last earnings report?
Camurus AB reported an EPS of kr1.67 in its last earnings report, missing expectations of kr2.367. Following the earnings report the stock price went down -24.03%.
Which hedge fund is a major shareholder of Camurus AB?
Currently, no hedge funds are holding shares in SE:CAMX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Camurus AB
Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
CAMX Company Deck
CAMX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a broadly positive strategic and financial picture for Camurus: full-year revenue and operating profitability improved materially, net cash increased significantly, regulatory approvals and U.S. FDA acceptance (PDUFA set) support upcoming launches, Brixadi royalties showed strong growth, and early-stage R&D (CAM2056) delivered compelling data. At the same time, the company faces notable short-term headwinds: Q4 revenue and product sales were down due to a U.K. distribution change and FX effects, quarter operating profit contracted, access/reimbursement barriers in several large European markets constrain Buvidal upside, and timing uncertainty remains for the SORENTO readout and some milestone revenues. Management provided constructive 2026 guidance while flagging planned increases in OpEx tied to U.S. launch preparation. Overall, strengths in commercial traction, cash position, approvals, and pipeline momentum outweigh the near-term operational and market-access challenges.View all SE:CAMX earnings summariesCAMX Stock 12 Month Forecast
Average Price Target
kr685.00
▲(3.01% Upside)
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
BioArctic AB Class B
―
Vicore Pharma Holding AB
―
Xspray Pharma AB
―
Options Prices
Currently, No data available
---